A5080878936- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Chronic Lymphocytic Leukemia Research
- Metabolism and Genetic Disorders
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Clinical Nutrition and Gastroenterology
- Diet and metabolism studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Parathyroid Disorders and Treatments
- Peripheral Neuropathies and Disorders
- Medical Imaging Techniques and Applications
- Research on Leishmaniasis Studies
- Glycogen Storage Diseases and Myoclonus
- Amino Acid Enzymes and Metabolism
- Neutropenia and Cancer Infections
- Infant Nutrition and Health
- Ubiquitin and proteasome pathways
- T-cell and Retrovirus Studies
Hospital de Clínicas
2016-2025
Hospital Británico
2015-2025
Universidad La República
2024
Universidad de la República de Uruguay
2010-2024
University Hospital Ostrava
2023
Universidad de Montevideo
2021-2023
The University of Texas MD Anderson Cancer Center
2021
Hospital Central de las Fuerzas Armadas
2020-2021
Ithaka Harbors
2019
Seattle University
2019
In contrast to the upfront setting in which role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation a first remission patients multiple myeloma (MM) is well established, or allogeneic HCT has not been extensively studied MM relapsing after primary therapy. The International Myeloma Working Group together Blood and Marrow Transplant Clinical Trials Network, American Society Transplantation, European Transplantation convened meeting experts to: (1)...
Waldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we aim to investigate the clinical, therapy, outcome patterns of WM in America.We retrospectively analyzed diagnosed between 1991 2019 24 centers seven countries. The study outcomes were overall survival (OS) progression-free (PFS).We identified 159 cases (median age 67 years, male 62%). Most (95%) symptomatic at diagnosis. International...
Key Points Patients with AA amyloidosis and age ≥65 years, eGFR <45 ml/min per 1.73 m 2 , N -terminal type-B natriuretic peptide >1000 ng/L and/or >130 at diagnosis have poorer survival. Proteinuria >3.0 g/24 hours <35 identify patients high risk of progression to end-stage kidney failure. Prognostic stratification in can be easily made by staging systems, similarly AL transthyretin amyloidosis. Background The is involved almost 100% cases amyloidosis, a rare disease caused...
Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real-world global demographic and outcome data are scarce. We collected on baseline characteristics outcomes from 61 725 patients with newly diagnosed MM who underwent upfront AHCT between 2013 2017 nine national/international registries. The primary endpoint was overall survival (OS), the secondary endpoints were progression-free (PFS), relapse incidence (RI) non-relapse...
Fifteen patients affected by Huntington9s chorea were divided into two groups, 9slow9 and 9fast9, according to IQ scores on the Wechsler-Bellevue scale, some motor performance tests. A possible correlation was looked for between biochemical data (cerebrospinal fluid (CSF), homovanillic acid (HVA), 5-hydroxyindolacetic (5HIAA) levels, plasma dopamine-beta-hydroxylase (DBH), dopamine (DA) uptake platelets), clinical (duration of illness, severity symptoms, age patients, scores, 9fast9 groups)....
PURPOSE Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease caused by the human leukemia virus type 1. Real-world data of ATLL in Latin America are lacking. PATIENTS AND METHODS We analyzed patients with (acute, lymphomatous, chronic, and smoldering) encountered 11 American countries between 1995 2019. Treatment response was assessed according to 2009 consensus report. Survival curves were estimated using Kaplan-Meier method log-rank test. RESULTS identified 253 patients; 226...
Background Accurate tissue typing in amyloidosis is essential to provide appropriate therapy for individual patients.
Introducción: En el año 2020, la Organización Mundial de Salud (OMS) declaró pandemia a enfermedad por coronavirus (COVID-19). SARS-COV-2 genera compromiso predominantemente pulmonar, aunque también se ha observado una infección sistémica que afecta sistema hematopoyético y coagulación. A pesar los notables avances en su comprensión, virus continúa activo resulta gran interés práctico contar con parámetros biológicos permitan alertarnos sobre posible evolución desfavorable.Metodología:...
The aim of this study was to describe clinical and survival characteristics transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public private healthcare facilities. We included 1293 diagnosed 2010 2018. A great disparity outcomes both groups observed. Late diagnosis low access adequate frontline therapy ASCT institutions probably explain these differences. Patients treated novel drug induction protocols, followed by...
<b><i>Introduction:</i></b> Rituximab was the first monoclonal antibody approved for treatment of B-cell non-Hodgkin lymphoma (NHL) expressing CD20 antigen. This has also potential to be used as a specific fluorescent and radiolabel agent targeting NHL. <b><i>Objective:</i></b> To rituximab with technetium-99m (<sup>99m</sup>Tc) or Cy7 evaluate both probes imaging agents <b><i>Methods:</i></b> derivatized...
Primary plasma cell leukemia (pPCL) is an infrequent and aggressive disorder. The prognosis still very poor, the optimal treatment remains to be established. A retrospective, multicentric, international observational study was performed. Patients from 9 countries of Latin America (LATAM) with a diagnosis pPCL between 2012 2020 were included. 72 patients Treatment based on thalidomide in 15%, proteasome inhibitors (PI)-based triplets 38% chemotherapy plus IMIDs and/or PI 29%. mortality rate...
"Prognostication of survival and progression to dialysis in AA amyloidosis." Amyloid, 24(sup1), pp. 136–137
PURPOSE Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes very young population are scarce. PATIENTS AND METHODS We analyzed characteristics, response to treatment, survival 103 patients with newly MM age 40 years or younger compared 256 41-50 957 51 older. RESULTS There were no statistical differences sex, isotype, International Scoring System, renal involvement,...
Vascular endothelial growth factor (VEGF) is one of the classic factors to tumor-induced angiogenesis in several types, including melanoma. Bevacizumab a humanized monoclonal antibody directed against VEGF.To radiolabel with 177-Lutetium as potential radioimmunotherapy agent for melanoma.Bevacizumab was derivatized DOTA-NHS-ester at 4 ºC 18 h. DOTABevacizumab radiolabeled 177LuCl3 (15 MBq/mg) 37 1 The studies were performed healthy and B16F1 tumor-bearing C57BL/6J mice 24 48 h (n = 5)....
Multiple myeloma is a disease of the elderly. However, 40% patients are diagnosed before 65 years old. Outcomes regarding age as prognostic factor in MM heterogeneous. We retrospectively analyzed clinical characteristics, response to treatment and survival 282 with active newly-diagnosed multiple myeloma, comparing results between younger older than years. The frequency those 66 was 53.2%. Younger presented more aggressive disease, advanced Durie-Salmon stage (85.3% vs 73.5%; p = 0.013),...
Multiple Myeloma (MM) is a malignant hematologic disorder and the second most common blood cancer. Interleukin-6 (IL-6) has been identified as crucial factor for proliferation survival of MM cells overexpression IL-6 receptor being studied molecular target therapeutic diagnostic use in myelomas other comorbidities. Tocilizumab humanized monoclonal antibody that binds IL-6R. We aim to label evaluate Fab(Tocilizumab) with 99mTechnetium or Cy7 potential imaging agents. IL-6R distribution was...
PURPOSE Infections are a significant cause of morbidity and mortality in patients with multiple myeloma (MM). In Latin America, data on infectious complications this patient population lacking. METHODS We conducted prospective cohort study newly diagnosed MM (NDMM) seven American countries between June 2019 May 2020. Patients active disease, therapy, follow-up 6 months from the time diagnosis were included. Our primary end point was number events that required hospitalization for ≥ 24 hours....